China Medipharm Insights - June 2000


Regular Price: USD 1,000.00

Special Price USD 700.00

30% OFF

* Required Fields

Regular Price: USD 1,000.00

Special Price USD 700.00


Be the first to review this product

Table of Contents

China Medipharm Insights - June 2000, China Medipharm InsightsMarket AnalysisAnalysis of China Pharmaceutical Industry in 1999 and 2000IndustryCommerceImport and ExportOutlook for 2000COMPANY PROFILESSanofi-Synthelabo Expands In ChinaSmithKline Beecham Receives Patents For Rosiglitazone Maleate In ChinaQuanxing Co. Ltd Forms Strategic Alliance with Tsinghua Univ.Anke Establishes An IndustrializationBase For Genetic Engineering of DrugsTianjin Pharmaceutical Group Co. Ltd To Be EstablishedHarbin Pharma To Ship Penicillin Potassium To USBeijing Double Crane Expands Rapidly through M&AGuangdong Xinbeijiang Pharma Booming on Export BusinessJilin Grand Pharmacy to Open Chain Stores in the USZhonglian Pharmacy Expands into WuhanYuxi Pharma Becomes part of Biochemical Engineering Technology Research CenterImport Drug MarketAnalysis Of Import Drug Market In ShanghaiDRUG CONSUMPTIONAnalysis of Oral Hy0spoglycemic Drug Market In ShanghaiDISEASE PROFILESMorbidity of ChronicDiseases Rose In ShenzhenColorectal Cancer Tends To Attack Younger ChineseIncidence Of Prostatic Diseases RisingOccurrence of Venereal Disease Keeps Rising In ChinaTuberculosis Control In Beijing up To International High LevelProduct NewsFive Pharmaceutical Research Achievements AuctionedKang Sai De Guishen Anti-pain Compound Worth US$36 MillionViagra Passes Clinical Trials in ChinaAcutobin Injection Launched By Huitian BiopharmaGenetic Engineering Bivalent Live Vaccine DevelopedNew Anti-Malaria Drug DevelopedNew Vascular Compounds MarketedLukang Simvastatin Passed EvaluationFluroxacin Glucose InjectionKangyu Pharma to Launch LevofloxacinGenetically Engineered Interferon aa-1b Granted Class I Drug Production PermitAttenuated Chicken Pox Vaccine MarketedAnti-drugging New Drug to Enter international MarketsNew Anti-pain Agent Hyperin DevelopedTsinghua University Biochip Into CommercializationBioChip Tech of No.4 Military Medical University TransferredRules & RegulationsNew “Good Supply Practice” ReleasedRegulations On Drug Retail Chain Stores Come On StageTrials Of Trans-regional Drug Retail Store Chains Start OutRegulation On Foreign-Funded Medical Institutions Released2000 First Drug Review Meeting Held By SDASDA Designates Clinical Trial Training CentersSETC Encourages Foreign Investment In New Drug R&DSDA Bans Medical Institutions From Selling Drugs Except To PatientsFramework of BasicMedical Insurance System Set UpDalian Commences Medical Insurance System ReformNanjing To Release New Medical Insurance ProgramNEWS IN BRIEFChina Pharma Industry Performed Well In 2000Q1Phase I of Human Genome Project Completed Ahead Of ScheduleMedical Misdiagnosis Rate Is 27.8 percent In ChinaRx and OTC Drug Classification Put Into Practice In TianjinQingdao Benefits From Medical ReformShandong Trials Rx and OTC ClassificationShandong Readjusts Drug PricesJiangxi Holds Price Bidding For Drug ProcurementFujian Takes MeasuresTo Curb Soaring Medical ExpenseZhejiang Pharma Sector Realized 32 percent Profit Growth in 2000Q1Five Hospitals In Wuhan To Be Punished For Receiving Large Illegal Drug DiscountPlanned Vaccination Improved In Inner MongoliaHealth Care Expenditure Surges In Wuhan Health Care Expenditure Rises In Chengdu

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.